MARC状态：审校 文献类型：西文图书 浏览次数：71
- 题名/责任者:
- Management of chemotherapy-induced nausea and vomiting : new agents and new uses of current agents / edited by Rudolph M. Navari.
- 出版发行项:
- Cham : Springer, 2016.
- ISBN:
- 9783319270142 (hbk.)
- ISBN:
- 9783319270166 (ebk.)
- 载体形态项:
- viii, 181 pages : illustrations ; 24 cm.
- 附加个人名称:
- Navari, Rudolph M., editor.
- 论题主题:
- Medicine.
- 论题主题:
- Pharmacology.
- 论题主题:
- Oncology.
- 论题主题:
- Chemotherapy.
- 中图法分类号:
- R96
- 书目附注:
- Includes bibliographical references and index.
- 内容附注:
- 1. Introduction -- 2. The Physiology and Pharmacology of Nausea and Vomiting Induced by Anti-Cancer Chemotherapy in Humans -- 3. First Generation 5HT-3 Receptor Antagonists -- 4. Second Generation Serotonin (5-HT3) Receptor Antagonist Palonosetron -- 5. The Role of Neurokinin-1 Receptor Antagonists in CINV -- 6. Olanzapine for the prevention of Chemotherapy-Induced Nausea and Vomiting -- 7. Gabapentin for the Prevention of CINV -- 8. Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy -- 9. Clinical Management of CINV -- 10. Treatment of Chemotherapy-Induced Nausea -- 11. Conclusions -- 12. Future Directions.
- 摘要附注:
- This book provides a comprehensive review of new agents, a detailed description of new uses of current agents, and an integration of the available agents in clinical practice. A description of a detailed clinical approach provides clinical practitioners with the most up-to-date recommendations for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in various clinical settings. CINV is one of the most feared treatment related toxicities. Patient surveys for the past thirty years consistently demonstrate patients perception of deterioration in quality of life due to chemotherapy treatments. The introduction of the antiemetics, serotonin 5-HT3 receptor antagonists and the neurokinin-1 receptor antagonists, have improved the control of chemotherapy-induced emesis, but the treatment of chemotherapy-induced nausea remains a significant clinical problem. Patients continue to have quality of life issues which prevent normal functioning during active treatment. New agents such as the second generation 5-HT3 receptor antagonist palonosetron and the new neuroknin-1 receptor antagonists rolapitant and netupitant are being introduced into clinical practice, and it is anticipated that these new agents will improve the control of CINV. Agents such as olanzapine (a FDA approved anti-psychotic), gabapentin (a FDA approved neuroleptic), and ginger (a food additive), which have been used primarily for other indications, are now being tested as potential, effective antiemetics. This work represents the first available comprehensive summary that details all new antiemetic agents and, particularly, their clinical role in treating patients; an important reference for practitioners seeking to improve the quality of life of patients undergoing chemotherapy.
全部MARC细节信息>>